[PDF] Top 20 A randomized, double blind, placebo controlled phase III trial of duloxetine in Japanese fibromyalgia patients
Has 10000 "A randomized, double blind, placebo controlled phase III trial of duloxetine in Japanese fibromyalgia patients" found on our website. Below are the top 20 most common "A randomized, double blind, placebo controlled phase III trial of duloxetine in Japanese fibromyalgia patients".
A randomized, double blind, placebo controlled phase III trial of duloxetine in Japanese fibromyalgia patients
... Because fibromyalgia is asso- ciated with neuropsychiatric symptoms, the BDI-II was used to assess improvement in these ...the duloxetine group than in the placebo ...the duloxetine group ... See full document
13
A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis
... 354 randomized patients, 161 in the duloxetine group and 162 in the placebo group completed the ...the duloxetine group than the placebo ...of patients that were more ... See full document
13
A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia
... The duloxetine group improved signifi cantly more than the placebo group at all visits through Week 8, as well as at Week 18, for the BPI average pain score and at all visits through Week 8, as well as Weeks ... See full document
12
Duloxetine in the treatment of generalized anxiety disorder
... of duloxetine, and was a randomized, double blind, placebo-controlled trial, conducted at sites throughout the US and ...label phase where 887 patients were ... See full document
10
<p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>
... A randomized, double-blind, open-label phase II trial eval- uated the ef fi cacy and safety of erlotinib in combination with tivantinib versus erlotinib in combination with pla- cebo in ... See full document
20
Novel oral targeted therapies in inflammatory bowel disease
... UC patients have been found to have a low intrinsic phosphatidylcholine content that reduces intestinal mucus barrier function, making it more susceptible to inflammation and ulceration (58, ...a double ... See full document
37
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
... in patients with mild-to-moderate Alzheimer’s disease ...24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which ... See full document
6
A randomized, double blind, multicenter, placebo controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
... 14-week trial was also con- ducted in patients with FM from 16 countries (Australia, Canada, Denmark, France, Germany, India, Italy, Korea, Mexico, Portugal, Spain, Sweden, Switzerland, The Neth- erlands, ... See full document
10
Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
... in patients with mCRC by the ...a randomized, double-blind, placebo- controlled phase III trial with 813 patients that evaluated the effect of ... See full document
6
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
... international, randomized, double-blind, placebo-controlled ...in patients with ...offer patients both a means of symptom relief and a treatment alternative to invasive ... See full document
11
Gastric cancer: current and evolving treatment landscape
... of patients with HER2-positive gastric or GEJ cancer from ...for patients with HER2-positive advanced gastric or GEJ ...cancer patients with HER2 amplification defined by fluorescence in situ ... See full document
5
Secukinumab in the treatment of psoriasis: patient selection and perspectives
... psoriasis patients who require rapid clearance of their ...certain patients may benefit from more rapid response than others, such as patients with sig- nificantly impaired quality of ...Discouraged ... See full document
8
Colorectal cancer in Chinese patients: current and emerging treatment options
... Abstract: Colorectal cancer is the second most common cancer in Hong Kong and its inci- dence is rising in economically developed Chinese cities, including Hong Kong and Shanghai. Several studies conducted in the ... See full document
12
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
... randomized to receive two doses of FTY720 ...(core phase) and at months 7–12 (extension ...extension phase of the trial, and the previous placebo group was randomized to the two ... See full document
9
Future prospects in the treatment of erectile dysfunction: focus on avanafil
... of patients in which gene therapy will be useful, including diabetic, aging, and in ...through Phase I clinical trial for ...a Phase I trial with no control ... See full document
9
Current perspective on rituximab in rheumatic diseases
... in patients affected by RA, non-Hodgkin lymphoma and other autoimmune diseases: 90 live births (22 premature and one extremely premature births), 33 miscarriages, 28 elective terminations, one late fetal loss and ... See full document
14
Everolimus – a new approach in the treatment of renal cell carcinoma
... Abstract: With the increasing understanding of the biology of the disease and the development of targeted therapy, there has been a paradigm shift in the treatment of clear cell metastatic renal cell carcinoma (mRCC). ... See full document
10
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
... drug-naïve patients with inadequate glycemic control (baseline A1c of ...26-week, double-blind, parallel-group study enrolled 655 participants who were randomized to receive alogliptin ...in ... See full document
12
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
... the placebo/erlotinib combination in three randomised phase II/III trials: ARQ 197 – 209 study (n=167 from the USA/European Union (EU)), MARQUEE study (n=1048 from the USA/EU) and ATTENTION study ... See full document
8
Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
... mCRC patients who were refractory or intolerant to standard treatments other than regorafenib were recruited in this study in ...in patients, such as neutropenia, leukopenia and anemia, were ...mCRC ... See full document
10
Related subjects